Y. Gong

发表

Envelope Conformational Changes Induced by Human Immunodeficiency Virus Type 1 Attachment Inhibitors Prevent CD4 Binding and Downstream Entry Events

James E. Robinson, R. Colonno, P. Clapham, 2006, Journal of Virology.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (B

N. Meanwell, D. Langley, R. Colonno, 2013, Journal of medicinal chemistry.

Regioselective N1- and N2-heterocycloalkylation of N1-sulfonyl-1,2,3-triazoles

Y. Zhang, Tao Wang, Baosheng Li, 2020 .

Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine.

N. Abraham, A. Kappas, G. Wormser, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitors of HIV-1 attachment. Part 11: the discovery and structure-activity relationships associated with 4,6-diazaindole cores.

N. Meanwell, J. Kadow, Zhong Yang, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.

Zheng Yang, Fang Zhao, Timothy P Spicer, 2003, Journal of medicinal chemistry.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity

N. Meanwell, R. Colonno, J. Kadow, 2009, Journal of medicinal chemistry.

Inhibitors of HIV-1 attachment. Part 7: indole-7-carboxamides as potent and orally bioavailable antiviral agents.

N. Meanwell, P. Shi, K. Yeung, 2013, Bioorganic & medicinal chemistry letters.

A survey of core replacements in indole-based HIV-1 attachment inhibitors.

T. Spicer, N. Meanwell, P. Shi, 2019, Bioorganic & medicinal chemistry letters.

Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates

M. Connelly, B. Robbins, R. V. Srinivas, 1993, Antimicrobial Agents and Chemotherapy.

Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives.

T. Spicer, N. Meanwell, P. Shi, 2009, Bioorganic & medicinal chemistry letters.

Potentiation of the stavudine anti-human immunodeficiency virus activity by 5-fluorouracil

P. Lin, Y. Gong, B. Robinson, 1996, Antimicrobial agents and chemotherapy.

Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates

D. Marshall, R. V. Srinivas, A. Fridland, 1994, Antimicrobial Agents and Chemotherapy.

5-Amino-4-imidazolecarboxamide riboside potentiates the metabolism and anti-human immunodeficiency virus activity of 2',3'-dideoxyinosine.

R. V. Srinivas, A. Fridland, Y. Gong, 1993, Molecular pharmacology.

BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

David A. Stock, R. Colonno, W. Blair, 2000, Antimicrobial Agents and Chemotherapy.

Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.

N. Meanwell, J. Kadow, Tao Wang, 2013, Bioorganic & medicinal chemistry letters.

In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

N. Meanwell, M. Krystal, J. Kadow, 2012, Antimicrobial Agents and Chemotherapy.

In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043

D. Langley, L. Alexander, M. Krystal, 2010, Antimicrobial Agents and Chemotherapy.

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.

N. Meanwell, D. Langley, R. Colonno, 2018, Journal of medicinal chemistry.

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

R. Colonno, R. Rose, B. Terry, 1996, Proceedings of the National Academy of Sciences of the United States of America.

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

Timothy P. Spicer, Ronald E. Rose, T. Spicer, 2000, Antimicrobial Agents and Chemotherapy.

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

Zheng Yang, Tao Wang, Robert Fridell, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns.

T. Spicer, N. Meanwell, P. Shi, 2009, Bioorganic & medicinal chemistry letters.

Inhibitors of HIV-1 attachment. Part 8: the effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors.

T. Spicer, N. Meanwell, P. Shi, 2013, Bioorganic & medicinal chemistry letters.